These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 30623365

  • 1. Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer.
    Fernandes MS, Sanches JM, Seruca R.
    Adv Exp Med Biol; 2018; 1110():35-53. PubMed ID: 30623365
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S, Mukherji D, Shamseddine A.
    Int J Mol Sci; 2015 Sep 23; 16(9):22976-88. PubMed ID: 26404261
    [Abstract] [Full Text] [Related]

  • 4. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul 23; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 5. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS.
    PLoS One; 2016 Jul 23; 11(3):e0151865. PubMed ID: 26991109
    [Abstract] [Full Text] [Related]

  • 6. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.
    Int J Clin Exp Pathol; 2014 Jul 23; 7(9):5927-39. PubMed ID: 25337237
    [Abstract] [Full Text] [Related]

  • 7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec 23; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 8. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E.
    J Exp Clin Cancer Res; 2019 Jan 28; 38(1):41. PubMed ID: 30691487
    [Abstract] [Full Text] [Related]

  • 9. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A, Sundström J, Lintunen M, Jokilehto T, Kytölä S, Kaare M, Vainionpää R, Orpana A, Österlund P, Ristimäki A, Carpen O, Ristamäki R.
    Int J Cancer; 2017 Feb 15; 140(4):922-929. PubMed ID: 27879995
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, Pawlik TM.
    Surg Oncol; 2018 Jun 15; 27(2):280-288. PubMed ID: 29937183
    [Abstract] [Full Text] [Related]

  • 11. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.
    Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX.
    World J Gastroenterol; 2019 Feb 21; 25(7):808-823. PubMed ID: 30809081
    [Abstract] [Full Text] [Related]

  • 12. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.
    BMC Cancer; 2016 Jul 26; 16():531. PubMed ID: 27461218
    [Abstract] [Full Text] [Related]

  • 13. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 14. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
    Moiseyenko VM, Moiseyenko FV, Yanus GA, Kuligina ES, Sokolenko AP, Bizin IV, Kudriavtsev AA, Aleksakhina SN, Volkov NM, Chubenko VA, Kozyreva KS, Kramchaninov MM, Zhuravlev AS, Shelekhova KV, Pashkov DV, Ivantsov AO, Venina AR, Sokolova TN, Preobrazhenskaya EV, Mitiushkina NV, Togo AV, Iyevleva AG, Imyanitov EN.
    Clin Drug Investig; 2018 Jun 07; 38(6):553-562. PubMed ID: 29470838
    [Abstract] [Full Text] [Related]

  • 15. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
    Kosmidou V, Oikonomou E, Vlassi M, Avlonitis S, Katseli A, Tsipras I, Mourtzoukou D, Kontogeorgos G, Zografos G, Pintzas A.
    Hum Mutat; 2014 Mar 07; 35(3):329-40. PubMed ID: 24352906
    [Abstract] [Full Text] [Related]

  • 16. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A, Lai C, McDonald S, Suraweera N, Sengupta N, Propper D, Dorudi S, Silver A.
    Exp Mol Pathol; 2013 Feb 07; 94(1):103-8. PubMed ID: 22982087
    [Abstract] [Full Text] [Related]

  • 17. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.
    Gut; 2009 Sep 07; 58(9):1234-41. PubMed ID: 19474002
    [Abstract] [Full Text] [Related]

  • 18. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
    Lo Nigro C, Ricci V, Vivenza D, Granetto C, Fabozzi T, Miraglio E, Merlano MC.
    World J Gastroenterol; 2016 Aug 14; 22(30):6944-54. PubMed ID: 27570430
    [Abstract] [Full Text] [Related]

  • 19. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
    Bozzao C, Varvara D, Piglionica M, Bagnulo R, Forte G, Patruno M, Russo S, Piscitelli D, Stella A, Resta N.
    Int J Biol Markers; 2012 Dec 27; 27(4):e366-74. PubMed ID: 23125007
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E, León A, Grávalos C, Cámara JC, Feliú J, Sanchíz B, Caldés T, Díaz-Rubio E.
    Mol Diagn Ther; 2015 Dec 27; 19(6):397-408. PubMed ID: 26341080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.